2022 World Conference on Lung Cancer (ePosters)-EP08.02-017. Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data

EP08.02-017. Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data

Back to course

Pdf Summary

This document presents a real-world study on the time on treatment (rwToT) for patients with metastatic non-small cell lung cancer (mNSCLC) who were treated with anti-EGFR tyrosine kinase inhibitors (TKIs). The study was conducted in Israel and included patients with EGFR driver mutations. The researchers aimed to compare the rwToT estimates with data from clinical trials and other real-world studies.<br /><br />The study population consisted of newly diagnosed Stage IV NSCLC patients with EGFR mutations who started TKI treatment between January 2017 and December 2020. Data was obtained from the national cancer registry and the Maccabi Healthcare Services (MHS) database, which contains longitudinal data on each patient's clinical interactions.<br /><br />The results showed that the median rwToT for patients treated with older TKIs was 9.4 months, with 37.66% of patients still on treatment at 12 months and 12.99% at 24 months. For patients treated with osimertinib, the median rwToT was 19.2 months, with 70.70% still on treatment at 12 months and 43.20% at 24 months.<br /><br />The study also analyzed demographic and clinical characteristics of the patients. The median age at index was 68.00 years, and the majority of patients were female. The analysis showed no significant differences in socioeconomic status, comorbidities, or other clinical characteristics between the two treatment groups.<br /><br />The researchers concluded that rwToT estimates for patients treated with anti-EGFR TKIs in the real world are comparable to data from clinical trials and other real-world studies. They also noted that their cohort included patients with poorer performance status who would not typically be included in clinical trials, allowing for the analysis of a real-world population.<br /><br />These findings provide valuable insights into the treatment duration and outcomes of patients with mNSCLC receiving anti-EGFR TKIs in a real-world setting.

Asset Subtitle

Lior Apter

Meta Tag

Speaker Lior Apter

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

time on treatment

rwToT

metastatic non-small cell lung cancer

mNSCLC

anti-EGFR tyrosine kinase inhibitors

TKIs

Israel

EGFR driver mutations

clinical trials

real-world studies